Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00619 ...
Drug Name Imatinib
Molecular Weight 493.6027
Molecular Formula C29H31N7O
CAS Number 152459-95-5
SMILES CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
External Links
DRUGBANK DB00619
PubChem Compound 5291
PDR 24310
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.0 - 3.0 - DRUGBANK
Melting Point 226.0 ℃ 226 ℃ DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 98.0 % 98 % DRUGBANK
Bioavailability 98.0 % 98(87-111) % PO, oral; The Pharmacological Basis of Therapeutics
C Max 2600.0 ng/ml 2.6±0.8 mcg/ml PO, oral; The Pharmacological Basis of Therapeutics
T Max 3.0 h 2-4 h DRUGBANK
T Max 3.3 h 3.3±1.1 h PO, oral; The Pharmacological Basis of Therapeutics
Clearance 11.0 L/h 8.0-14 L/h Gastrointestinal stromal tumor; Chronic myelogenous leukemia; patients; gaining weight ↑ ; DRUGBANK
Clearance 0.20 L/h/kg 3.3±1.2 ml/min/kg The Pharmacological Basis of Therapeutics
Clearance 0.20 L/h/kg 3.3 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 6.2 L/kg 6.2±2.2 L/kg The Pharmacological Basis of Therapeutics
Volume of Distribution 3.9 L/kg 3.9 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 18.0 h 18 h normal,healthy; DRUGBANK
Half-life 40.0 h 40 h normal,healthy; DRUGBANK
Half-life 22.0 h 22±4 h The Pharmacological Basis of Therapeutics
Half-life 22.0 h 22 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 68.0 % 68 % Faeces excretion; DRUGBANK
Eliminate Route 13.0 % 13 % Urinary excretion; DRUGBANK
Eliminate Route 5.0 % 5 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 20.0 % 20 % Faeces excretion; Unchanged drug; DRUGBANK
Eliminate Route 50.0 % 5 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 95.0 % 95 % DRUGBANK
Protein Binding 95.0 % 95 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 340.0 mg/m2/day 340 mg/m2/day PO, oral Imatinib Mesylate imatinib mesylate PDR
Max dose for children 600.0 mg/day 600 mg/day PO, oral Imatinib Mesylate imatinib mesylate PDR
Max dose for adolescents 340.0 mg/m2/day 340 mg/m2/day PO, oral Imatinib Mesylate imatinib mesylate PDR
Max dose for adolescents 600.0 mg/day 600 mg/day PO, oral Imatinib Mesylate imatinib mesylate PDR
Max dose for adults 800.0 mg/day 800 mg/day PO, oral Imatinib Mesylate imatinib mesylate PDR
Max dose for geriatric 800.0 mg/day 800 mg/day PO, oral Imatinib Mesylate imatinib mesylate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1